查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715752

抗苗勒氏管激素检测市场（按产品、成分、应用和最终用户划分）—2025 年至 2030 年全球预测

Anti-Mullerian Hormone Test Market by Product, Component, Applications, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

抗苗勒氏管激素检测市场预计在 2024 年达到 3.0541 亿美元，2025 年达到 3.4021 亿美元，复合年增长率为 11.48%，到 2030 年达到 5.8648 亿美元。

主要市场统计数据
基准年2024年 3.0541亿美元
预计2025年 3.4021亿美元
预测年份 2030 5.8648亿美元
复合年增长率（%） 11.48%

抗苗勒氏管激素 (AMH) 测试为了解卵巢储备和生育能力提供了重要见解，并已成为女性生殖健康评估的基石。在个人化医疗和先进诊断技术驱动临床决策的时代，AMH 测试为临床医生和患者提供了评估卵巢功能的重要工具。本报告探讨了 AMH 测试市场的不断发展的动态，讨论了科学和技术突破以及对患者护理和结果的更广泛影响。

在过去的几年中，检测的灵敏度和特异性得到了显着提高，彻底改变了检测格局。透过研究和开发，AMH 测试已成为了解卵巢症候群 (PCOS) 和卵巢早衰等疾病的宝贵诊断标记。此外，医疗保健提供者对早期诊断和早期疗育益处的认识不断提高，导致了检测通讯协定的广泛采用。这份全面的摘要对市场驱动因素、挑战和机会进行了详细的分析，为决策者和专家提供了一个平衡的观点。

透过研究当前趋势、技术进步和市场细分，本摘要为相关人员提供了在快速发展的行业中导航所需的见解。以下讨论为理解该市场的策略转变及其对未来成长的影响奠定了基础。

改变抗苗勒氏管激素检测市场

近年来，由于技术的进步、临床指南的不断发展以及患者期望的变化，AMH 检测领域发生了显着变化。检测方法开发的创新提高了诊断测试的可靠性和速度，从而缩短了周转时间并改善了临床结果。曾经依赖劳动密集流程的技术现在受益于自动化和数位集成，简化了工作流程并提高了数据准确性。

监管核准流程变得更加严格和透明，确保新的测试方法符合严格的品质和安全标准。这种转变不仅增强了医护人员的信心，也为采用新的检测套组和设备铺平了道路。同时，诊断製造商和研究机构之间的合作创造了持续创新的环境。这样的伙伴关係加速了科学发现向可操作的诊断工具的转换。

此外，市场参与企业越来越关注以患者为中心的解决方案，强调便利性和准确性。新兴技术正在满足就地检验和自我检测套件的需求，使得在传统临床环境之外更容易进行诊断。这些全行业的变化不仅彻底改变了测试的方式，而且还重新调整了主要市场参与者的策略重点，为更具活力和竞争性的格局奠定了基础。

AMH 测试市场的关键细分洞察

详细的細項分析揭示了影响 AMH 测试市场的几个关键因素。第一个细分将产品分为照护现场（POC）和自我检测套件等类别，每个类别都针对不同的使用者需求和偏好。这种基于产品的细分强调了为临床环境和家庭测试场景提供快速且可存取的解决方案的重要性。

从组件的角度来看，分析区分了仪器和试剂/试剂套件。这些设备分为桌上型和可携式，突显了市场对适用于各种医疗环境的精密测试设备和行动诊断解决方案的关注。同时，试剂和套件部分包括客製化和标准检测。这种差异凸显了开发广泛适用的标准检测套组以及针对特定临床需求量身定制的诊断解决方案的双重方法。

考虑到应用，市场主要受 AMH 测试在卵巢储备评估、卵巢症候群诊断和卵巢早衰预测中的作用所驱动。每个应用都提供了对患者生殖健康的独特见解，并需要特定的分析方法和精确度。最后，最终用户部分汇集了诊断实验室、生育诊所、医院和研究机构。这种分类体现了相关人员的多样化生态系统，每位参与者都有独特的需求和营运挑战，推动了一系列针对不同细分市场的创新解决方案。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 生殖健康问题和不孕症问题的增加导致对 AMH 测试的需求增加。
      • 政府措施和优惠的报销政策推动了 AMH 检测的普及
      • 随着晚期怀孕趋势的增加，对可靠生育指标的需求也随之增加。
    • 限制因素
      • 高昂的营运成本和严格的报销政策阻碍了抗苗勒氏管激素检测市场的发展
    • 机会
      • 推广 AMH 检测作为更广泛的不孕症治疗领域个人化医疗的重要工具
      • 增强的数位平台，实现无缝 AMH 测试预约和结果管理，从而改善用户体验
    • 任务
      • 影响抗穆氏管荷尔蒙检测扩展的重要法规
  • 市场区隔分析
    • 产品：为方便个人健康管理，自检套件的需求不断增加
    • 应用：随着不孕症问题的增加，使用抗穆氏管荷尔蒙测试来评估卵巢储备的情况正在扩大
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 抗苗勒氏管激素检测市场（依产品）

  • POC 测试
  • 自检套件

7. 抗苗勒氏管激素检测市场（依成分）

  • 装置
    • 桌上型装置
    • 可携式分析仪
  • 试剂和套件
    • 客製化检测
    • 标准检测

第八章抗苗勒氏管激素检测市场（依应用）

  • 卵巢储备评估
  • 卵巢的诊断
  • 卵巢早衰的预测

第九章抗苗勒氏管激素检测市场（依最终用户划分）

  • 诊断实验室
  • 不孕不育诊所
  • 医院
  • 研究组织

10.美洲抗苗勒氏管激素检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区抗苗勒氏管激素检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲抗苗勒氏管激素检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbexa Limited
  • Ansh Labs LLC
  • Athenese-Dx
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMerieux SA
  • BioVendor-Laboratorni Medicina AS
  • Chengdu VACURE Biotechnology Co., Ltd.
  • CTK Biotech, Inc.
  • Cusabio Technology LLC
  • Danaher Corporation
  • Eagle Biosciences, Inc.
  • Elabscience Bionovation Inc.
  • Epitope Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio Europe NV by HU Group Holdings, Inc.
  • Goldsite Diagnostics Inc.
  • Healthy Human Labs Limited（Vitall）
  • Kamiya Biomedical Company
  • LifeSpan BioSciences, Inc.
  • London Gynaecology Limited
  • Meridian Bioscience, Inc.
  • Monobind Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Vitrosens Biotechnology Co., Ltd.
Product Code: MRR-BC3400CDF7AF

The Anti-Mullerian Hormone Test Market was valued at USD 305.41 million in 2024 and is projected to grow to USD 340.21 million in 2025, with a CAGR of 11.48%, reaching USD 586.48 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 305.41 million
Estimated Year [2025] USD 340.21 million
Forecast Year [2030] USD 586.48 million
CAGR (%) 11.48%

The anti-mullerian hormone (AMH) test has emerged as a cornerstone in the assessment of female reproductive health, offering critical insights into ovarian reserve and fertility potential. In an era where personalized medicine and advanced diagnostic techniques are driving clinical decisions, the AMH test provides both clinicians and patients with a significant tool for evaluating ovarian function. This report explores the evolving dynamics of the AMH testing market, discussing not only the scientific and technological breakthroughs but also the broader implications on patient care and treatment outcomes.

Over the past few years, significant strides in assay sensitivity and specificity have transformed the testing landscape. Research and development have cemented the role of the AMH test as an invaluable diagnostic marker for understanding conditions such as polycystic ovary syndrome (PCOS) and premature ovarian failure. Moreover, increasing awareness among healthcare providers about the benefits of early diagnosis and intervention has led to broader adoption of testing protocols. This comprehensive summary offers an in-depth look at market drivers, challenges, and opportunities, providing a balanced perspective that caters to decision-makers and experts alike.

By studying current trends, technological advancements, and market segmentation, this summary equips stakeholders with the necessary insights to navigate a rapidly evolving industry. The discussion that follows lays the foundation for understanding the strategic shifts within this market and their implications for future growth.

Transformative Shifts in the Testing Landscape

Recent years have witnessed transformative shifts in the AMH testing landscape, driven by advanced technologies, evolving clinical guidelines, and changing patient expectations. Innovations in assay development have enhanced both the reliability and speed of diagnostic tests, thereby reducing turnaround times and improving clinical outcomes. Methodologies that once relied on labor-intensive processes now benefit from automation and digital integration, leading to streamlined workflows and improved data precision.

Regulatory approval processes have become more robust and transparent, ensuring that new testing methods meet stringent quality and safety standards. This shift not only instills greater confidence among healthcare providers but also paves the way for the adoption of novel test kits and instruments. Meanwhile, collaborations between diagnostic companies and research institutions are fostering an environment of continuous innovation. Such partnerships accelerate the translation of scientific discoveries into practical diagnostic tools.

Furthermore, market entrants are increasingly focused on patient-centered solutions that emphasize both convenience and accuracy. Emerging technologies cater to the need for point-of-care testing and self-check kits, making diagnostics more accessible outside traditional clinical settings. These industry-wide changes are not only revolutionizing the way tests are performed but are also realigning the strategic priorities of key market players, setting the stage for a more dynamic and competitive landscape.

Key Segmentation Insights in the AMH Testing Market

A detailed segmentation analysis reveals several pivotal factors shaping the AMH testing market. The first segmentation divides products into categories such as point-of-care (POC) testing and self-check kits, each targeting different user requirements and settings. Such product-based segmentation underscores the importance of offering rapid, accessible solutions that cater both to clinical environments and at-home testing scenarios.

From a component perspective, the analysis differentiates between instruments and reagents & kits. Instruments are sub-segmented into benchtop devices and portable analyzers, highlighting the market's focus on precision laboratory instruments as well as mobile diagnostic solutions suited to a variety of healthcare settings. Concurrently, the reagents and kits segment encompasses both customized assays and standard assays. This distinction emphasizes the dual approach of developing tailored diagnostic solutions that meet specific clinical needs alongside widely applicable standard test kits.

When considering applications, the market is primarily driven by the roles of the AMH test in ovarian reserve assessment, polycystic ovary syndrome diagnosis, and premature ovarian failure prediction. Each application offers unique insights into a patient's reproductive health, demanding specific analytical approaches and levels of accuracy. Finally, the end-user segmentation brings together diagnostic laboratories, fertility clinics, hospitals, and research institutes. This classification showcases the diverse ecosystem of stakeholders involved, each with unique demands and operational challenges, thus driving a range of innovative solutions tailored to distinct market segments.

Based on Product, market is studied across POC Testing and Self-check Kits.

Based on Component, market is studied across Instruments and Reagents & Kits. The Instruments is further studied across Benchtop Devices and Portable Analyzers. The Reagents & Kits is further studied across Customized Assays and Standard Assays.

Based on Applications, market is studied across Ovarian Reserve Assessment, Polycystic Ovary Syndrome Diagnosis, and Premature Ovarian Failure Prediction.

Based on End User, market is studied across Diagnostic Laboratories, Fertility Clinics, Hospitals, and Research Institutes.

Key Regional Insights and Market Dynamics

Geographical insights are crucial in understanding the global dynamics of the AMH testing market. The analysis highlights distinct regional trends, with the Americas being characterized by well-established healthcare infrastructures coupled with high patient awareness and rapid adoption of advanced diagnostic technologies. In contrast, the Europe, Middle East & Africa region presents a blend of mature markets and emerging economies where regulatory reforms and increasing investment in healthcare are driving market expansion.

The Asia-Pacific region offers substantial growth opportunities due to its vast population, rising income levels, and a growing focus on women's health. Innovations in diagnostic technologies and improvements in healthcare accessibility are helping bridge the gap between urban and rural healthcare services. These regions exhibit unique market behaviors and growth trajectories influenced by local economic conditions, regulatory environments, and cultural perceptions regarding health and wellness.

Understanding these regional nuances is essential for companies aiming to tailor their strategies and for stakeholders seeking to capitalize on untapped market potential. By analyzing regional performance alongside technological advancements, the report provides a strategic framework that aligns localized market strategies with the overarching global trends in AMH testing.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights and Competitive Landscape

The competitive landscape of the AMH testing market is marked by a blend of established industry giants and dynamic newcomers, each contributing unique strengths and innovative practices. Notable companies such as Abbexa Limited, Ansh Labs LLC, and Athenese-Dx lead the market with their cutting-edge technologies and robust R&D initiatives. Global players including Bio-Rad Laboratories, Inc., Bio-Techne Corporation, and bioMerieux S.A. are leveraging their extensive portfolios to provide comprehensive diagnostic solutions.

Other key players such as BioVendor - Laboratorni Medicina A.S., Chengdu VACURE Biotechnology Co., Ltd., CTK Biotech, Inc., and Cusabio Technology LLC are gaining traction by focusing on niche segments and specialized assay development. Corporations like Danaher Corporation, Eagle Biosciences, Inc., and Elabscience Bionovation Inc. are continuously innovating, pushing the envelope with advanced instrumentation and high-sensitivity reagents.

Major entities such as Epitope Diagnostics, Inc., F. Hoffmann-La Roche Ltd., and Fujirebio Europe N.V. by H.U. Group Holdings, Inc. underscore the market's commitment to quality and accuracy. Additional influential companies include Goldsite Diagnostics Inc., Healthy Human Labs Limited (Vitall), Kamiya Biomedical Company, LifeSpan BioSciences, Inc., and London Gynaecology Limited, whose contributions have been instrumental in elevating market standards. Meridian Bioscience, Inc., Monobind Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Tosoh Corporation, and Vitrosens Biotechnology Co., Ltd. further enrich this competitive mix. This diverse array of companies ensures that the market remains dynamic, continuously evolving through innovation and strategic collaborations.

The report delves into recent significant developments in the Anti-Mullerian Hormone Test Market, highlighting leading vendors and their innovative profiles. These include Abbexa Limited, Ansh Labs LLC, Athenese-Dx, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, bioMerieux S.A., BioVendor - Laboratorni Medicina A.S., Chengdu VACURE Biotechnology Co., Ltd., CTK Biotech, Inc., Cusabio Technology LLC, Danaher Corporation, Eagle Biosciences, Inc., Elabscience Bionovation Inc., Epitope Diagnostics, Inc., F. Hoffmann-La Roche Ltd., Fujirebio Europe N.V. by H.U. Group Holdings, Inc., Goldsite Diagnostics Inc., Healthy Human Labs Limited (Vitall), Kamiya Biomedical Company, LifeSpan BioSciences, Inc., London Gynaecology Limited, Meridian Bioscience, Inc., Monobind Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Tosoh Corporation, and Vitrosens Biotechnology Co., Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to focus on several strategic initiatives to successfully navigate and thrive in the rapidly evolving AMH testing market. It is imperative to invest in the development and integration of advanced diagnostic technologies that enhance accuracy and reduce testing turnaround time. Embracing automation and digital health innovations can significantly streamline operational workflows, thereby optimizing overall efficiency.

Leaders should also prioritize the expansion of product portfolios to include both point-of-care and self-check testing options, catering to a diverse range of end users who have varied needs. The dual approach of refining instruments-whether through benchtop devices or portable analyzers-and innovating around reagents and kits, both customized and standard, can facilitate robust market penetration.

In addition, forging strategic partnerships with diagnostic laboratories, fertility clinics, hospitals, and research institutes can accelerate innovation and help in effectively addressing region-specific challenges. Keeping abreast of regional regulatory changes, and tailoring strategies accordingly, will further help in capitalizing on emerging market opportunities. Finally, enhancing consumer education about the clinical benefits of the AMH test can drive increased adoption, ensuring that both clinical practitioners and patients are well informed and confident about the diagnostic value of these tests.

Conclusion: Strategic Outlook for the AMH Testing Market

In conclusion, the AMH testing market is poised for significant transformation driven by technological innovations, evolving clinical standards, and a proactive approach to addressing patient needs. The integration of advanced diagnostic instruments with versatile assay kits has not only augmented testing accuracy but also redefined service delivery models across varied clinical settings. The comprehensive segmentation analysis reveals that innovations in product design, component flexibility, application specificity, and end-user engagement play an integral role in market evolution.

The regional outlook underscores distinct growth dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each contributing uniquely to global market performance. The competitive landscape, enriched by influential players spanning from established companies to emerging disruptors, reinforces the market's commitment to continuous innovation and high-quality diagnostics.

As the market evolves, stakeholders are challenged to remain adaptable and forward-thinking. The strategic recommendations outlined herein emphasize the importance of investment in R&D, technological integration, and customer-centric methodologies. This strategic outlook provides a robust framework for navigating the future, ensuring that industry leaders are well-equipped to harness emerging opportunities and drive sustainable growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of reproductive health issues and infertility driving demand for AMH testing
      • 5.1.1.2. Government initiatives and favorable reimbursement policies support AMH test uptake
      • 5.1.1.3. Growing inclination towards late pregnancies fuels the need for reliable fertility indicators
    • 5.1.2. Restraints
      • 5.1.2.1. High operational costs and limited reimbursement policies constrain the anti-mullerian hormone test market
    • 5.1.3. Opportunities
      • 5.1.3.1. Promoting AMH testing as an essential tool for personalized medicine within the broader fertility landscape
      • 5.1.3.2. Enhancing digital platforms for seamless AMH test booking and result management to improve user experience
    • 5.1.4. Challenges
      • 5.1.4.1. Significant regulations affecting the expansion of anti-mullerian hormone testing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing demand for self-check kits for convenience and personal health management
    • 5.2.2. Applications: Expanding application of anti-mullerian-hormone-test for ovarian reserve assessment with rising fertility issues
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Mullerian Hormone Test Market, by Product

  • 6.1. Introduction
  • 6.2. POC Testing
  • 6.3. Self-check Kits

7. Anti-Mullerian Hormone Test Market, by Component

  • 7.1. Introduction
  • 7.2. Instruments
    • 7.2.1. Benchtop Devices
    • 7.2.2. Portable Analyzers
  • 7.3. Reagents & Kits
    • 7.3.1. Customized Assays
    • 7.3.2. Standard Assays

8. Anti-Mullerian Hormone Test Market, by Applications

  • 8.1. Introduction
  • 8.2. Ovarian Reserve Assessment
  • 8.3. Polycystic Ovary Syndrome Diagnosis
  • 8.4. Premature Ovarian Failure Prediction

9. Anti-Mullerian Hormone Test Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Fertility Clinics
  • 9.4. Hospitals
  • 9.5. Research Institutes

10. Americas Anti-Mullerian Hormone Test Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anti-Mullerian Hormone Test Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Mullerian Hormone Test Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Beli's launches at-home test kits revolutionize personalized reproductive health
    • 13.3.2. Siemens Healthineers introduced a Novel Assay for Assessing Ovarian Reserve
    • 13.3.3. ARUP Laboratories introduced MenoCheck to revolutionize menopausal management
    • 13.3.4. The Advent of the Elecsys Anti-Mullerian Hormone Plus immunoassay for Enhanced Accessibility and Early Detection
    • 13.3.5. Innovative At-Home Fertility Test by Fertilly for Understanding Reproductive Health through Anti-Mullerian Hormone Analysis
    • 13.3.6. Strategic Acquisition of Meridian Bioscience by SD Biosensor and SJL Partners for Enhanced Growth and Global Impact
    • 13.3.7. Randox Quality Control Introduces Advanced Acusera AMH Control for Enhanced Reproductive Testing
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbexa Limited
  • 2. Ansh Labs LLC
  • 3. Athenese-Dx
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Bio-Techne Corporation
  • 6. bioMerieux S.A.
  • 7. BioVendor - Laboratorni Medicina A.S.
  • 8. Chengdu VACURE Biotechnology Co., Ltd.
  • 9. CTK Biotech, Inc.
  • 10. Cusabio Technology LLC
  • 11. Danaher Corporation
  • 12. Eagle Biosciences, Inc.
  • 13. Elabscience Bionovation Inc.
  • 14. Epitope Diagnostics, Inc.
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. Fujirebio Europe N.V. by H.U. Group Holdings, Inc.
  • 17. Goldsite Diagnostics Inc.
  • 18. Healthy Human Labs Limited (Vitall)
  • 19. Kamiya Biomedical Company
  • 20. LifeSpan BioSciences, Inc.
  • 21. London Gynaecology Limited
  • 22. Meridian Bioscience, Inc.
  • 23. Monobind Inc.
  • 24. Siemens Healthineers AG
  • 25. Thermo Fisher Scientific Inc.
  • 26. Tosoh Corporation
  • 27. Vitrosens Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTI-MULLERIAN HORMONE TEST MARKET MULTI-CURRENCY
  • FIGURE 2. ANTI-MULLERIAN HORMONE TEST MARKET MULTI-LANGUAGE
  • FIGURE 3. ANTI-MULLERIAN HORMONE TEST MARKET RESEARCH PROCESS
  • FIGURE 4. ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ANTI-MULLERIAN HORMONE TEST MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. ANTI-MULLERIAN HORMONE TEST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-MULLERIAN HORMONE TEST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-MULLERIAN HORMONE TEST MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. ANTI-MULLERIAN HORMONE TEST MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 279. ANTI-MULLERIAN HORMONE TEST MARKET, FPNV POSITIONING MATRIX, 2024